nuke
Bluelighter
- Joined
- Nov 7, 2004
- Messages
- 4,191
Effects of Post-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
http://www.clinicaltrials.gov/ct/show/NCT00218361
Inclusion Criteria:
18 Years-55 Years, Genders Eligible for Study: Both
Opioid dependent, as determined by the structured clinical interview for DSM-IV (SCID) and Addiction Severity Index (ASI)
Positive urine test for opiates
Willing to use an adequate form of contraception for the duration of the study
Reads and writes English
Exclusion Criteria:
Psychiatric illness, as determined by the DSM-IV criteria
History of or current neurological disease, including structural abnormalities, seizures, infection, peripheral neuropathy, and head traumas
History of cardiovascular disease, myocardial infarction, chest pain, or edema
Systolic blood pressure greater than 160 mm Hg or less than 95 mm Hg; PR diastolic blood pressure greater than 95 mm Hg
Pulmonary disease, including obstructive pulmonary disease, cor pulmonale, tuberculosis, and asthma
Systemic disease (e.g., endocrinopathies, liver or kidney failure, myxedema, hypothyroidism, Addison's disease, autoimmune disease)
Current alcohol or sedative drug dependence
Pregnant or breastfeeding
Currently receiving treatment for opioid dependence
Known phobia of injections
Started August 2005; currently in progress and accepting new participants.
Contact
Please refer to this study by ClinicalTrials.gov identifier NCT00218361
Lisa Sulkowski 313-993-3966
United States, Michigan
Wayne State University, Detroit, Michigan, 48207, United States; Recruiting
Mark Greenwald, PhD 313-993-3965
Study chairs or principal investigators
Mark Greenwald, PhD, Principal Investigator, Wayne State University
(Please do not PM me in regards to this, I am not affiliated with this research)
Drug dependence is often characterized by severe drug seeking behavior. Learning to understand, predict, and control this maladaptive choice behavior may lead to improved prevention and treatment strategies. HYD is a drug that is currently used as a cough suppressant and to relieve pain. The purpose of this study is to determine the extent to which opioid drug seeking behavior by heroin dependent individuals can be reduced by environmental factors, including supplemental opioid drug availability, drug price, and alternative non-drug reinforcers. Specifically, this study will determine whether knowledge of post-session HYD availability influences drug seeking behavior in heroin dependent individuals, who are maintained on buprenorphine during their participation.
Participants in this observational study will take part in multiple trials in which they have the opportunity to choose either HYD or money. On the first two experimental days, prior to choice sessions, participants will receive a sample of the drug doses that can be chosen, 12 and 24 mg of HYD. During test sessions, participants will have 12 opportunities to choose either drug or money. Participants will use a computer to earn choices. Respiration rate, oxygen saturation, heart rate, and blood pressure will be monitored throughout choice trials. Supplemental HYD will be made available following some choice sessions. Self-report questionnaires will be completed at different times during the study. Participants will be maintained on buprenorphine throughout the study, with a minimum 2-week lead before the experiment, and a fixed 3-week detoxification after study completion.
http://www.clinicaltrials.gov/ct/show/NCT00218361
Inclusion Criteria:
18 Years-55 Years, Genders Eligible for Study: Both
Opioid dependent, as determined by the structured clinical interview for DSM-IV (SCID) and Addiction Severity Index (ASI)
Positive urine test for opiates
Willing to use an adequate form of contraception for the duration of the study
Reads and writes English
Exclusion Criteria:
Psychiatric illness, as determined by the DSM-IV criteria
History of or current neurological disease, including structural abnormalities, seizures, infection, peripheral neuropathy, and head traumas
History of cardiovascular disease, myocardial infarction, chest pain, or edema
Systolic blood pressure greater than 160 mm Hg or less than 95 mm Hg; PR diastolic blood pressure greater than 95 mm Hg
Pulmonary disease, including obstructive pulmonary disease, cor pulmonale, tuberculosis, and asthma
Systemic disease (e.g., endocrinopathies, liver or kidney failure, myxedema, hypothyroidism, Addison's disease, autoimmune disease)
Current alcohol or sedative drug dependence
Pregnant or breastfeeding
Currently receiving treatment for opioid dependence
Known phobia of injections
Started August 2005; currently in progress and accepting new participants.
Contact
Please refer to this study by ClinicalTrials.gov identifier NCT00218361
Lisa Sulkowski 313-993-3966
United States, Michigan
Wayne State University, Detroit, Michigan, 48207, United States; Recruiting
Mark Greenwald, PhD 313-993-3965
Study chairs or principal investigators
Mark Greenwald, PhD, Principal Investigator, Wayne State University
(Please do not PM me in regards to this, I am not affiliated with this research)
Last edited by a moderator: